Variations in photodynamic diagnosis for bladder cancer due to the quality of endoscopic equipment

Nohara, Takahiro; Kamijima, Taiki; Fukuda, Ryouichi; Kano, Hiroshi; Shimada, Takafumi; Nakano, Taito; Kato, Yuki; Kadomoto, Suguru; Iwamoto, Hiroaki; Yaegashi, Hiroshi; Iijima, Masashi; Kawaguchi, Shohei; Shigehara, Kazuyoshi; Izumi, Kouji; Kadono, Yoshifumi; Mizokami, Atsushi

doi:10.1016/j.pdpdt.2021.102628

Cited by 7 publications

(2 citation statements)

References 24 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…These limitations should be considered when interpreting the results. Furthermore, the use of 5-aminolevulinic acid has recently been incorporated into the photodynamic diagnosis, which may further improve the prognosis of non-muscle-invasive BC, and future developments are expected (18).…”

Section: Kaplan-meier Curve For Overall (A) Cancer-specific (B) and P...mentioning

confidence: 99%

Squamous or Glandular Differentiation Predicts Poor Prognosis in pT1 Urothelial Carcinoma

Nakagawa

Iwamoto

Makino

et al. 2022

In Vivo

Self Cite

View full text Add to dashboard Cite

Background: The aim of this study was to evaluate the prognosis of patients with T1N0M0 urothelial carcinoma with squamous differentiation (UCSD) or glandular differentiation (UCGD) because it has not been determined whether these variant histologies behave more aggressively than pure urothelial carcinoma (PUC). Patients and Methods: Ninety-nine patients diagnosed with pT1N0M0 bladder cancer and treated conservatively with transurethral resection of bladder tumor at Kanazawa University Hospital between 2007 and 2019 were included in this study. The overall survival, cancer-specific survival (CSS), and recurrence-free survival of the variant histology and PUC groups were evaluated and compared. Results: The variant histology group had significantly lower overall survival (p=0.006) and CSS (p=0.0095) than the PUC group did. Variant histology was found to be an independent prognostic factor in univariate and multivariate analyses for overall survival and CSS. On the other hand, no significant difference in progression-free survival was observed between the two groups (p=0.439). However, the variant histology group had significantly lower overall survival (p=0.004) and CSS (p=0.004) after progression. Conclusion: The prognosis for patients with pT1 bladder cancer with UCSD or UCGD treated conservatively with transurethral resection of bladder tumor was poor. Considering the worse prognosis of these patients after stage progression, early radical cystectomy could be recommended. Patients and MethodsAmong patients with BC receiving treatment at Kanazawa University Hospital from 2007 to 2019, those who were initially diagnosed with T1N0M0 and treated conservatively with transurethral resection of bladder tumor (TURBT) were selected. Patients who underwent cystectomy or radiation therapy were excluded. Patients with pathologically diagnosed PUC, UCSD, or UCGD were included in this study. We retrospectively investigated 2365

show abstract

Section: Kaplan-meier Curve For Overall (A) Cancer-specific (B) and P...mentioning

confidence: 99%

Squamous or Glandular Differentiation Predicts Poor Prognosis in pT1 Urothelial Carcinoma

Nakagawa

Iwamoto

Makino

et al. 2022

In Vivo

Self Cite

View full text Add to dashboard Cite

show abstract

“…The combination of the cystoscopy technique with the fluorescence phenomenon is an important advance in the field of bladder cancer diagnosis. However, discrepancies and variations in the type and the quality of the used endoscopic apparatus affect the management outcomes in photodiagnosis-assisted resection [35].…”

Section: Fluorescence Diagnosis Of Bladder Cancermentioning

confidence: 99%

Superficial bladder cancer diagnosis — the deliberate choice between fluorescent diagnosis and optical biopsy

Khatib

2022

Oncol Clin Pract

View full text Add to dashboard Cite

Bladder carcinoma in situ (CIS) is a potentially invasive tumor whose early detection is a key step to ensuring the preservation of the bladder, reducing mortality, and improving the quality of patients' life. The early diagnosis of bladder cancer requires a sensitive technique that can detect the lesion to determine its stage and grade. ALA induced-PpIX makes it possible to detect tumors with 90% sensitivity. ALA hexyl ester (hALA) increases the sensitivity to 95%. Macroscopic techniques require a histological biopsy to define the tumor invasiveness. Imaging with Fibered Optic Confocal Fluorescence Microscopy allows the optical sectioning of examined tissues providing images with subcellular resolution after labeling with adequate fluorescent dye chosen based on the sensitivity of the used device. Available fluorescent agents are compatible with used devices; however, their toxicity and mutagenesis studies are unsatisfactory. During imaging, an optical fiber is introduced into the bladder via the urethra and placed in contact with the bladder wall. The distinction between the different types of epithelial cells is based on the cell size, morphology, and signal intensity. Although not fully adopted for clinical application, the FOCM represents a real asset that reduces invasiveness and complements the fluorescence-based endoscopy.

show abstract

Intravesical BCG therapy with photodynamic diagnosis-guided transurethral resection of bladder tumors improves recurrence-free survival

Nakagawa

Nohara

Naito

et al. 2023

Photodiagnosis and Photodynamic Therapy

View full text Add to dashboard Cite

Variations in photodynamic diagnosis for bladder cancer due to the quality of endoscopic equipment

Cited by 7 publications

References 24 publications

Squamous or Glandular Differentiation Predicts Poor Prognosis in pT1 Urothelial Carcinoma

Squamous or Glandular Differentiation Predicts Poor Prognosis in pT1 Urothelial Carcinoma

Superficial bladder cancer diagnosis — the deliberate choice between fluorescent diagnosis and optical biopsy

Intravesical BCG therapy with photodynamic diagnosis-guided transurethral resection of bladder tumors improves recurrence-free survival

Contact Info

Product

Resources

About